SpyGlass Pharma, Inc.
- Tickers
- SGP
- Headquarters
- Not recorded
- SEC CIK
- 0001778922
- Website
- Not recorded
Closing prices
Latest close, 33.32
Prices start 6 Feb 2026.
| Date | Close |
|---|---|
| 26.40 | |
| 26.18 | |
| 27.83 | |
| 27.55 | |
| 27.50 | |
| 28.22 | |
| 27.69 | |
| 28.50 | |
| 29.68 | |
| 29.32 | |
| 29.35 | |
| 29.29 | |
| 29.13 | |
| 28.35 | |
| 28.00 | |
| 26.73 | |
| 26.75 | |
| 26.68 | |
| 26.42 | |
| 26.68 | |
| 27.12 | |
| 26.82 | |
| 27.10 | |
| 26.42 | |
| 26.55 | |
| 27.10 | |
| 27.20 | |
| 26.80 | |
| 25.71 | |
| 26.00 | |
| 26.35 | |
| 23.74 | |
| 25.22 | |
| 25.20 | |
| 22.61 | |
| 23.37 | |
| 25.91 | |
| 24.44 | |
| 22.46 | |
| 22.65 | |
| 21.07 | |
| 22.22 | |
| 21.22 | |
| 20.75 | |
| 23.87 | |
| 24.52 | |
| 24.73 | |
| 25.03 | |
| 24.94 | |
| 24.52 | |
| 24.45 | |
| 24.49 | |
| 23.63 | |
| 23.52 | |
| 23.65 | |
| 23.00 | |
| 22.13 | |
| 22.94 | |
| 23.98 | |
| 24.41 | |
| 24.41 | |
| 25.06 | |
| 25.39 | |
| 23.41 | |
| 23.76 | |
| 24.14 | |
| 23.82 | |
| 24.27 | |
| 23.21 | |
| 22.24 | |
| 21.20 | |
| 21.89 | |
| 22.05 | |
| 20.84 | |
| 20.62 | |
| 20.17 | |
| 19.84 | |
| 19.26 | |
| 18.32 | |
| 18.36 | |
| 18.56 | |
| 19.47 | |
| 18.78 | |
| 18.74 | |
| 18.19 | |
| 17.97 | |
| 18.09 | |
| 18.44 | |
| 18.94 | |
| 17.56 | |
| 18.20 | |
| 18.70 | |
| 19.34 | |
| 19.67 | |
| 19.55 | |
| 18.81 | |
| 21.18 | |
| 21.65 | |
| 22.26 | |
| 19.47 | |
| 19.15 | |
| 19.09 | |
| 19.52 | |
| 20.46 | |
| 20.07 | |
| 22.52 | |
| 19.90 | |
| 19.99 | |
| 20.60 | |
| 20.76 | |
| 19.77 | |
| 20.02 | |
| 20.27 | |
| 20.54 | |
| 20.88 | |
| 20.49 | |
| 20.82 | |
| 21.62 | |
| 21.91 | |
| 22.72 | |
| 22.53 | |
| 22.68 | |
| 24.11 | |
| 23.68 | |
| 24.75 | |
| 25.31 | |
| 25.16 | |
| 24.85 | |
| 25.27 | |
| 25.17 | |
| 26.20 | |
| 25.78 | |
| 25.84 | |
| 27.23 | |
| 26.23 | |
| 26.51 | |
| 26.26 | |
| 26.60 | |
| 26.64 | |
| 26.93 | |
| 26.42 | |
| 26.10 | |
| 26.86 | |
| 28.28 | |
| 28.99 | |
| 28.94 | |
| 28.92 | |
| 27.50 | |
| 27.31 | |
| 27.52 | |
| 28.66 | |
| 28.96 | |
| 28.60 | |
| 29.33 | |
| 29.08 | |
| 27.96 | |
| 28.69 | |
| 28.16 | |
| 27.65 | |
| 27.07 | |
| 25.98 | |
| 25.44 | |
| 26.00 | |
| 26.50 | |
| 24.92 | |
| 25.59 | |
| 24.78 | |
| 23.90 | |
| 24.62 | |
| 24.92 | |
| 24.86 | |
| 23.92 | |
| 23.69 | |
| 24.72 | |
| 24.00 | |
| 24.60 | |
| 26.16 | |
| 27.71 | |
| 28.22 | |
| 28.48 | |
| 29.91 | |
| 30.90 | |
| 32.86 | |
| 32.51 | |
| 32.24 | |
| 33.64 | |
| 34.45 | |
| 34.45 | |
| 34.08 | |
| 36.95 | |
| 38.37 | |
| 34.18 | |
| 34.97 | |
| 33.32 |
Drugs
| Drug | Indications | Phase | Next catalyst | CT-VCA | Trials |
|---|---|---|---|---|---|
| Bimatoprost implant system | Cataract; Glaucoma; Ocular Hypertension | Phase 3 | None scheduled | 2 |
FDA-approved applications
No Drugs@FDA application has a sponsor name that matches this company.
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | Not reported in XBRL filings since 2015 | ||
| Net income (loss) | −19,864,000 USD | 1 Apr 2026 to 30 Jun 2026 FY2026 Q2 | 10-Q for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | 10,942,000 USD | 1 Apr 2026 to 30 Jun 2026 FY2026 Q2 | 10-Q for Research and development expense on sec.gov (opens in a new tab)Filed |
| Operating expenses | 21,967,000 USD | 1 Apr 2026 to 30 Jun 2026 FY2026 Q2 | 10-Q for Operating expenses on sec.gov (opens in a new tab)Filed |
| Cash and cash equivalents | 223,143,000 USD | At 30 Jun 2026 FY2026 Q2 | 10-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | Not reported in XBRL filings since 2015 | ||
| Total liabilities | 11,069,000 USD | At 30 Jun 2026 FY2026 Q2 | 10-Q for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | 232,364,000 USD | At 30 Jun 2026 FY2026 Q2 | 10-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 33,447,979 shares | At 29 Jul 2026 FY2026 Q2 | 10-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Apr 2026 to 30 Jun 2026 FY2026 Q2 | −19,864,000 USD | 10-Q filed 6 Aug 2026 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2026 to 31 Mar 2026 FY2026 Q2 | −13,818,000 USD | 10-Q filed 6 Aug 2026 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2025 to 31 Dec 2025 FY2025 | −39,869,000 USD | 10-K filed 26 Mar 2026 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2025 to 30 Jun 2025 FY2026 Q2 | −8,675,000 USD | 10-Q filed 6 Aug 2026 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2025 to 31 Mar 2025 FY2026 Q2 | −8,823,000 USD | 10-Q filed 6 Aug 2026 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2024 to 31 Dec 2024 FY2025 | −29,164,000 USD | 10-K filed 26 Mar 2026 on sec.gov (opens in a new tab)Filed |
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for SpyGlass Pharma, Inc. on Insider TradesLast 90 days of Form 4 filings, from 15 Aug 2026 (US Eastern dates).
- Buys code P
- None in this period
- Sells code S
- None in this period
- Other all other codes
- None in this period
Last transaction:
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.